TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable…
Medical - Devices
US, Andover [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -64.26 | 152.86 | 427.67 | |
| Graham Fair Price | 86.87 | 6.39 | 3.42 | |
| PEG | -82.91 | 0.24 | -1.38 | |
| Price/Book | -19.68 | 15.08 | 18.78 | |
| Price/Cash Flow | 34.28 | -50.53 | -76.88 | |
| Prices/Earnings | -69.14 | 49.31 | 159.80 | |
| Price/Sales | -21.75 | 24.84 | 31.74 | |
| Price/FCF | 34.28 | -50.53 | -76.88 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 4.69 | 0.62 | 0.59 | |
| Operating Margin | 299.94 | 0.13 | 0.03 | |
| ROA | 195.15 | 0.02 | < 0.005 | |
| ROE | 0.03 | 0.08 | 160.33 | |
| ROIC | < 0.005 | 0.02 | 334.51 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | < 0.005 | -6.16 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 1.09 | 3.77 | 245.45 | |
| EPS QOQ | 1.15 | 2.08 | 80.56 | |
| FCF QOQ | 0.76 | -0.42 | -44.93 | |
| Revenue QOQ | 0.22 | 0.19 | -12.99 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 119.73 | 118.11 | -1.36 | |
| Days Sales Outstanding (DSO) | 70.49 | 76.15 | 8.03 | |
| Inventory Turnover | 0.75 | 0.76 | 1.37 | |
| Debt/Capitalization | 0.79 | 0.76 | -3.30 | |
| Quick Ratio | 8.34 | 8.60 | 3.12 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 4.20 | 4.87 | 15.82 | |
| Cash | 12.09 | 10.69 | -11.61 | |
| Capex | -1.28 | -1.35 | -5.26 | |
| Free Cash Flow | -1.03 | -1.45 | -41.55 | |
| Revenue | 2.49 | 2.96 | 18.89 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad